US6402681083 - NKTR - 165417 (XNAS)
NEKTAR THERAPEUTICSCS Action
1,13 USD
Cours actuels de NEKTAR THERAPEUTICSCS
Bourse | Ticker | Devise | Dernier échange | Cours | Variation journalière | Variation journalière % |
---|---|---|---|---|---|---|
NASDAQ |
NKTR
|
USD
|
08.01.2025 22:58
|
1,13 USD
| 1,24 USD | -8,87 % |
London |
0UNL.L
|
USD
|
08.01.2025 19:44
|
1,14 USD
| 1,24 USD | -8,03 % |
Performance
Heute | Woche | Monat | 3 Monate | 6 Monate | 1 Jahr | 5 Jahre |
---|---|---|---|---|---|---|
0,00 % | 17,59 % | 10,24 % | -13,08 % | -9,60 % | 96,56 % | -94,81 % |
Firmenprofil zu NEKTAR THERAPEUTICSCS Aktie
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, squamous cell carcinoma of the head and neck, and adjuvant melanoma; phase 2 clinical trial for the treatment of renal cell carcinoma, non-small cell lung cancer, and urothelial cancer; phase 1/2A clinical trial to treat squamous cell carcinoma of the head and neck; phase 1/2 clinical trial for the treatment of solid tumors; and phase 1B clinical trial to treat COVID-19. It is also developing NKTR-358, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; NKTR-255, an IL-15 receptor agonist, which is in phase 1/2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer and colorectal cancer; and NKTR-262, a toll-like receptor agonist that is in phase 1/2 clinical trial to treat solid tumors, as well as various other drug candidates. The company has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. Nektar Therapeutics was incorporated in 1990 and is headquartered in San Francisco, California.
Investierte Fonds
Folgende Fonds haben in investiert: NEKTAR THERAPEUTICSCS investiert:
Fonds | Vol. in Mio 95,85 | Anteil (%) 0,22 % |
Unternehmensdaten zur NEKTAR THERAPEUTICSCS Aktie
Name NEKTAR THERAPEUTICSCS
Firma Nektar Therapeutics
Symbol NKTR
Website https://www.nektar.com
Heimatbörse
NASDAQ
WKN 165417
ISIN US6402681083
Wertpapierart Aktie
Sektor Healthcare
Branche Biotechnology
CEO Mr. Howard W. Robin
Marktkapitalisierung 236 Mio
Land Vereinigte Staaten von Amerika
Währung USD
Mitarbeiter 0,1 T
Adresse 455 Mission Bay Boulevard South, 94158 San Francisco
IPO Datum 1994-05-03
Aktien-Splits
Datum | Split |
---|---|
23.08.2000 | 2:1 |
Ticker Symbole
Name | Symbol |
---|---|
Frankfurt | ITH.F |
London | 0UNL.L |
NASDAQ | NKTR |
Weitere Aktien
Investoren die NEKTAR THERAPEUTICSCS die halten, haben auch folgende Aktien im Depot:
Die Finanzplattform MoneyPeak trackt und analysiert Investitionen und Portfolios.
Vom Wertpapier-Depot bis zum Crypto-Kauf.
Nützlich, simpel und kostenlos. Aktien, ETF, ETC, ETN, Indizes, Fonds, Anleihen, Zertifikate, Währungen, Optionen, Bezugsrechte.
Nützlich, simpel und kostenlos. Aktien, ETF, ETC, ETN, Indizes, Fonds, Anleihen, Zertifikate, Währungen, Optionen, Bezugsrechte.